80841-48-1
Chemical Structure
Asulacrine isethionate
Synonym(s): CI-921 isethionate; NSC 343499 isethionate
- CAS No.: 80841-48-1
- Formula:C26H30N4O8S2
- Molecular Weight:590.67
IUPAC Name: 9-((2-methoxy-4-(methylsulfonamido)phenyl)amino)-N,5-dimethylacridine-4-carboxamide 2-hydroxyethane-1-sulfonate
InChIKey: MWXDBWAFWBSGFA-UHFFFAOYSA-N
SMILES: O=C(C1=CC=CC2=C1N=C3C(C=CC=C3C)=C2NC4=CC=C(NS(=O)(C)=O)C=C4OC)NC.O=S(O)(CCO)=O
Biological Activity: Asulacrine isethionate (CI-921 isethionate) is a derivative of Amsacrine (HY-13551), a Topoisomerase II inhibitor and an anticancer agent. Asulacrine isethionate binds to DNA via intercalation, forming stable complexes with long residence times at DNA sites. Asulacrine isethionate mediates DNA breakage and DNA-protein cross-linking. Asulacrine isethionate exhibits anticancer activity against leukemia or lung cancer. Asulacrine isethionate can be used in research related to breast cancer, lung cancer, mouse solid tumors and leukemia[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Asulacrine isethionate | Asulacrine isethionate (CI-921 isethionate) is a derivative of Amsacrine (HY-13551), a Topoisomerase II inhibitor and an anticancer agent. Asulacrine isethionate binds to DNA via intercalation, forming stable complexes with long residence times at DNA sites. Asulacrine isethionate mediates DNA breakage and DNA-protein cross-linking. Asulacrine isethionate exhibits anticancer activity against leukemia or lung cancer. Asulacrine isethionate can be used in research related to breast cancer, lung cancer, mouse solid tumors and leukemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ganta S, et al. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. International journal of pharmaceutics. 2009 Feb 09;367(1-2):179-86. [Content Brief]
- [2]. Hays S J, et al. Deuterium, tritium, and carbon‐14 labeling of 9‐[[2‐methoxy‐4‐[(methylsulfonyl) amino] phenyl] amino]‐N, 5‐dimethyl‐acridinecarboxamide (CI‐921), a new antitumor agent[J]. Journal of Labelled Compounds and Radiopharmaceuticals, 1984, 21(6): 575-586.
- [3]. Gellerman G. Recent synthetic approaches to anti-cancer 9-anilinoacridines. A review[J]. Organic Preparations and Procedures International, 2012, 44(3): 187-221.
- [4]. Teitelbaum A M. Pre-clinical Drug Development of 9-aminoacridines for Malignant Glioma and Meropenem Prodrugs for Drug-Resistant Tuberculosis[M]. University of Minnesota, 2012.
Keywords
